问题 › 我们下一步该投哪里? › 专业服务
当合伙人薪酬奖励用任何计费工作填满工作台,而不是将下一位专业人士分配到毛利率最高的业务时,资本配置就会出错。 专业服务公司在此有一个特定困境——合伙人薪酬理性地支付人们<em>不去</em>销售公司最高利润的产品。在定价之前,计费利用率会因无人能归因的原因继续变动,而关于各业务线回报的辩论仍将是意见问题。
当合伙人薪酬奖励用任何计费工作填满工作台,而不是将下一位专业人士分配到毛利率最高的业务时,资本配置就会出错。 专业服务公司在此有一个特定困境——合伙人薪酬理性地支付人们不去销售公司最高利润的产品。在定价之前,计费利用率会因无人能归因的原因继续变动,而关于各业务线回报的辩论仍将是意见问题。
大多数公司根据去年的利用率目标以及哪些合伙人最努力争取本业务部门的人员编制来分配人员和新员工。两者都与哪种类型的业务产生最高增量毛利率无关。
有帮助的分析按两件事给每个业务或服务线排序——在当前实现率下每增加一名专业人士能产生的增量收入,以及这种利润在价格压力或杠杆稀释出现之前能维持多久。一条能快速填满利用率但一年内就会压缩利润的业务线,与一条能在多份业务中维持实现率高于目标的业务线是不同的。
输出应该是一条带停止规则的序列,而不是一份人员编制计划。哪个业务先扩、什么利用率阈值能为下一人提供资金,以及哪条实现率观察能说明序列已错。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 利用率目标按去年的计费小时数加一个百分比设定
✓ 没人能按下一位专业人士的业务毛利率给服务线排序
✓ 投资决策用维持合伙人杠杆的战略重要性而非实现率算术来辩护
通常会让情况更糟的做法。 把新业务均匀分配给合伙人以维持和平,这会让本可提升整体每合伙人收入的那个业务缺钱。
It is for you if you run or finance a professional services firm and budgets are set by last year plus a percentage. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家专业服务公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Aldergate Partners, a sample company profile used for testing rather than a customer — $88M revenue, 310 people.
Excerpt from a real Percision run · Quick Market Scan · sample company profile
The move. Re-align partner economics so the $85K diagnostic becomes the highest-compensated path to the $410K implementation.
The leak it closes. Partner-level incentive leakage that currently diverts 25% of diagnostic-eligible opportunities back to T&M work
The assumption it rests on. 15-of-22 partners approve compensation redesign within 60 days — the engine put the probability at 0.7.
| Investment required | $700K total over 36 months — $200K annual incentive pool × 3 years + $100K legal and change-management cost |
| Expected return | 3.4× cash-on-cash over 36 months (NPV $2.4M / $700K investment) on $58.0M current revenue base |
| Revenue, year 1 | +$1.2M incremental diagnostic and implementation revenue (15 additional diagnostics × $85K + 12 conversions × $410K) |
| Revenue, year 2 | +$2.4M cumulative incremental revenue |
| Revenue, year 3 | +$3.7M cumulative incremental revenue |
| Exit criteria | Terminate this move and revert to legacy compensation if (a) fewer than 12-of-22 partners approve redesign by Day 60, or (b) any top-3 account issues an RFP within 90 days of announcement, or (c) diagnostic-to-implementation conversion falls below 10-of-19 by December 31, 2026. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 增长组合框架, one of 29 engagements the platform runs. For 专业服务公司 it works through billable utilisation, realisation, revenue per partner and engagement gross margin, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
明确给耐久性定价。会衰减的回报需要一个明确的半衰期;一旦每个选项都带上这个,不同跨度的选项就能比较,而不是凭感觉。
通常投最强的,因为边际资金在那里能复利。修复最弱的部分只有在它构成对最强部分的约束时才值得做,否则不值得。
那就看可逆性。当两个选项回报相近时,选择能停掉的那个,因为你买到的信息价值超过估算之间的差异。
Materially, yes. Partner compensation rationally pays people not to sell the highest-margin product in the firm — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are billable utilisation, realisation, revenue per partner, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on billable utilisation and realisation. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית